Angiogenic gene-modified muscle cells for enhancement of tissue formation

Paolo De Coppi, Dawn Delo, Lynn Farrugia, Kavid Udompanyanan, James J. Yoo, Masashi Nomi, Anthony Atala, Shay Soker

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Engineering muscle tissue with inadequate vascularity may lead to fibrosis and loss of muscle function. In this study we combined the isolation and genetic engineering of myoblasts with tissue transplantation in an attempt to create well-vascularized muscle tissue. Myoblasts were obtained from a single explant of adult Lewis rat myofibers and transfected with a bicistronic plasmid encoding vascular endothelial growth factor (VEGF) and green fluorescent protein (GFP) or with a plasmid encoding a nonfunctional VEGF-alkaline phosphatase (AP) fusion protein. VEGF expression and GFP expression in vitro were, respectively, assessed by Western blot analysis ELISA and fluorescence microscopy, showing that the myoblasts were successfully expressing the recombinant proteins. The transfected cells were suspended in collagen type I and injected subcutaneously into nude mice. Analysis of the retrieved engineered muscle tissues by RT-PCR immunostaining and fluorescence showed expression of VEGF and GFP proteins. Immunohistochemical analysis of the muscle tissues 1, 3, and 4 weeks after implantation confirmed the muscle phenotype. Neovascularization and muscle tissue mass significantly increased with functional VEGF-transfected cells compared with nonfunctional VEGF-transfected cells. In conclusion, this study demonstrates that in vivo engineered muscle tissues improve their volumes when VEGF-expressing muscle cells are used.

Original languageEnglish
Pages (from-to)1034-1044
Number of pages11
JournalTissue Engineering
Volume11
Issue number7-8
DOIs
StatePublished - Jul 1 2005
Externally publishedYes

Fingerprint

Muscle Cells
Muscle
Vascular Endothelial Growth Factor A
Genes
Cells
Tissue
Muscles
Myoblasts
Green Fluorescent Proteins
Proteins
Plasmids
Tissue Transplantation
Transplantation (surgical)
Genetic Engineering
Genetic engineering
Recombinant proteins
Collagen Type I
Fluorescence microscopy
Phosphatases
Fluorescence Microscopy

ASJC Scopus subject areas

  • Biophysics
  • Cell Biology
  • Biotechnology

Cite this

De Coppi, P., Delo, D., Farrugia, L., Udompanyanan, K., Yoo, J. J., Nomi, M., ... Soker, S. (2005). Angiogenic gene-modified muscle cells for enhancement of tissue formation. Tissue Engineering, 11(7-8), 1034-1044. https://doi.org/10.1089/ten.2005.11.1034

Angiogenic gene-modified muscle cells for enhancement of tissue formation. / De Coppi, Paolo; Delo, Dawn; Farrugia, Lynn; Udompanyanan, Kavid; Yoo, James J.; Nomi, Masashi; Atala, Anthony; Soker, Shay.

In: Tissue Engineering, Vol. 11, No. 7-8, 01.07.2005, p. 1034-1044.

Research output: Contribution to journalArticle

De Coppi, P, Delo, D, Farrugia, L, Udompanyanan, K, Yoo, JJ, Nomi, M, Atala, A & Soker, S 2005, 'Angiogenic gene-modified muscle cells for enhancement of tissue formation', Tissue Engineering, vol. 11, no. 7-8, pp. 1034-1044. https://doi.org/10.1089/ten.2005.11.1034
De Coppi P, Delo D, Farrugia L, Udompanyanan K, Yoo JJ, Nomi M et al. Angiogenic gene-modified muscle cells for enhancement of tissue formation. Tissue Engineering. 2005 Jul 1;11(7-8):1034-1044. https://doi.org/10.1089/ten.2005.11.1034
De Coppi, Paolo ; Delo, Dawn ; Farrugia, Lynn ; Udompanyanan, Kavid ; Yoo, James J. ; Nomi, Masashi ; Atala, Anthony ; Soker, Shay. / Angiogenic gene-modified muscle cells for enhancement of tissue formation. In: Tissue Engineering. 2005 ; Vol. 11, No. 7-8. pp. 1034-1044.
@article{ad943fb580e345d087bb4a29dce7d335,
title = "Angiogenic gene-modified muscle cells for enhancement of tissue formation",
abstract = "Engineering muscle tissue with inadequate vascularity may lead to fibrosis and loss of muscle function. In this study we combined the isolation and genetic engineering of myoblasts with tissue transplantation in an attempt to create well-vascularized muscle tissue. Myoblasts were obtained from a single explant of adult Lewis rat myofibers and transfected with a bicistronic plasmid encoding vascular endothelial growth factor (VEGF) and green fluorescent protein (GFP) or with a plasmid encoding a nonfunctional VEGF-alkaline phosphatase (AP) fusion protein. VEGF expression and GFP expression in vitro were, respectively, assessed by Western blot analysis ELISA and fluorescence microscopy, showing that the myoblasts were successfully expressing the recombinant proteins. The transfected cells were suspended in collagen type I and injected subcutaneously into nude mice. Analysis of the retrieved engineered muscle tissues by RT-PCR immunostaining and fluorescence showed expression of VEGF and GFP proteins. Immunohistochemical analysis of the muscle tissues 1, 3, and 4 weeks after implantation confirmed the muscle phenotype. Neovascularization and muscle tissue mass significantly increased with functional VEGF-transfected cells compared with nonfunctional VEGF-transfected cells. In conclusion, this study demonstrates that in vivo engineered muscle tissues improve their volumes when VEGF-expressing muscle cells are used.",
author = "{De Coppi}, Paolo and Dawn Delo and Lynn Farrugia and Kavid Udompanyanan and Yoo, {James J.} and Masashi Nomi and Anthony Atala and Shay Soker",
year = "2005",
month = "7",
day = "1",
doi = "10.1089/ten.2005.11.1034",
language = "English",
volume = "11",
pages = "1034--1044",
journal = "Tissue Engineering",
issn = "1076-3279",
publisher = "Mary Ann Liebert Inc.",
number = "7-8",

}

TY - JOUR

T1 - Angiogenic gene-modified muscle cells for enhancement of tissue formation

AU - De Coppi, Paolo

AU - Delo, Dawn

AU - Farrugia, Lynn

AU - Udompanyanan, Kavid

AU - Yoo, James J.

AU - Nomi, Masashi

AU - Atala, Anthony

AU - Soker, Shay

PY - 2005/7/1

Y1 - 2005/7/1

N2 - Engineering muscle tissue with inadequate vascularity may lead to fibrosis and loss of muscle function. In this study we combined the isolation and genetic engineering of myoblasts with tissue transplantation in an attempt to create well-vascularized muscle tissue. Myoblasts were obtained from a single explant of adult Lewis rat myofibers and transfected with a bicistronic plasmid encoding vascular endothelial growth factor (VEGF) and green fluorescent protein (GFP) or with a plasmid encoding a nonfunctional VEGF-alkaline phosphatase (AP) fusion protein. VEGF expression and GFP expression in vitro were, respectively, assessed by Western blot analysis ELISA and fluorescence microscopy, showing that the myoblasts were successfully expressing the recombinant proteins. The transfected cells were suspended in collagen type I and injected subcutaneously into nude mice. Analysis of the retrieved engineered muscle tissues by RT-PCR immunostaining and fluorescence showed expression of VEGF and GFP proteins. Immunohistochemical analysis of the muscle tissues 1, 3, and 4 weeks after implantation confirmed the muscle phenotype. Neovascularization and muscle tissue mass significantly increased with functional VEGF-transfected cells compared with nonfunctional VEGF-transfected cells. In conclusion, this study demonstrates that in vivo engineered muscle tissues improve their volumes when VEGF-expressing muscle cells are used.

AB - Engineering muscle tissue with inadequate vascularity may lead to fibrosis and loss of muscle function. In this study we combined the isolation and genetic engineering of myoblasts with tissue transplantation in an attempt to create well-vascularized muscle tissue. Myoblasts were obtained from a single explant of adult Lewis rat myofibers and transfected with a bicistronic plasmid encoding vascular endothelial growth factor (VEGF) and green fluorescent protein (GFP) or with a plasmid encoding a nonfunctional VEGF-alkaline phosphatase (AP) fusion protein. VEGF expression and GFP expression in vitro were, respectively, assessed by Western blot analysis ELISA and fluorescence microscopy, showing that the myoblasts were successfully expressing the recombinant proteins. The transfected cells were suspended in collagen type I and injected subcutaneously into nude mice. Analysis of the retrieved engineered muscle tissues by RT-PCR immunostaining and fluorescence showed expression of VEGF and GFP proteins. Immunohistochemical analysis of the muscle tissues 1, 3, and 4 weeks after implantation confirmed the muscle phenotype. Neovascularization and muscle tissue mass significantly increased with functional VEGF-transfected cells compared with nonfunctional VEGF-transfected cells. In conclusion, this study demonstrates that in vivo engineered muscle tissues improve their volumes when VEGF-expressing muscle cells are used.

UR - http://www.scopus.com/inward/record.url?scp=24944554491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24944554491&partnerID=8YFLogxK

U2 - 10.1089/ten.2005.11.1034

DO - 10.1089/ten.2005.11.1034

M3 - Article

C2 - 16144439

AN - SCOPUS:24944554491

VL - 11

SP - 1034

EP - 1044

JO - Tissue Engineering

JF - Tissue Engineering

SN - 1076-3279

IS - 7-8

ER -